SWISS drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly and Novo Nordisk in the booming market, the Financial Times reported on Monday.
Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish demand, with experts boosting their sales forecasts for such treatments to as much as $150 billion by the early 2030s.
Be the first to comment